ProKidney grants 400,000 stock options to executive

PROKIDNEY CORP. reported that Chief Regulatory Officer Darin J. Weber received a grant of 400,000 employee stock options with an exercise price of $0.00 per share.

Accepted by SEC EDGAR 03/03/2026 - 07:58 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

PROKIDNEY CORP. reported that Chief Regulatory Officer Darin J. Weber received a grant of 400,000 employee stock options with an exercise price of $0.00 per share. The options vest in substantially equal monthly installments over four years beginning on March 1, 2026.

Insider Trade Summary

Grant/Award: 400,000 shares

Grant/Award 1 txn

Insider Weber Darin J.

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy)	400,000	$0.00	$0.00

Holdings After Transaction: Employee stock option (right to buy) — 400,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PROK (ProKidney Corp.) report?

ProKidney reported a grant of 400,000 employee stock options to Chief Regulatory Officer Darin J. Weber. These options are a form of equity compensation, giving him the right to buy company shares at a fixed price in the future.

Who received the 400,000 stock options in the latest PROK Form 4?

Chief Regulatory Officer Darin J. Weber received 400,000 employee stock options from ProKidney Corp. As a senior executive, this award aligns part of his compensation with the company’s equity, linking his potential upside to future company performance.

What is the exercise price of Darin Weber’s ProKidney stock options?

The 400,000 employee stock options granted to Darin J. Weber have an exercise price of $0.00 per share. This means he does not pay a cash exercise price to acquire shares when the options vest and are exercised.

How do the 400,000 ProKidney options granted to Darin Weber vest?

The option grant to Darin J. Weber vests in substantially equal monthly installments over four years, beginning on March 1, 2026. This structure encourages long-term service by gradually delivering the full award over an extended period.

Is the ProKidney insider transaction a purchase or an award?

The transaction is an award, not an open-market purchase. It is classified as a grant or other acquisition of 400,000 employee stock options, issued as part of compensation rather than being bought on the market by the executive.

How many ProKidney derivative securities does Darin Weber hold after this grant?

After the reported grant, Darin J. Weber holds a total of 400,000 derivative securities in the form of employee stock options. This figure reflects his position following the award described in the insider transaction report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weber Darin J.

(Last) (First) (Middle)

C/O PROKIDNEY CORP

2000 FRONTIS PLAZA BLVD, SUITE 250

(Street)

WINSTON-SALEM NC 27103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$2.24	03/01/2026		A		400,000		(1)	03/01/2036	Class A Common Stock	400,000	$0	400,000	D

Explanation of Responses:

1. The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026.

	/s/ James Coulston, attorney in fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.